Skip to content

News

High Volume Hospitals and Providers Improve Survival

High Volume Hospitals and Providers Improve Survival

(December 20, 2013)  Researchers have found that for women with advanced-stage ovarian cancer, being treated at a high volume hospital with a high volume provider, leads to improved survival.  The research was published online today in Gynecologic Oncology. Among patients with advanced-stage ovarian cancer, the provider combination of high volume hospital/high volume provider is an … Continued

Research

Partner Member Profile: Hope for Heather

Partner Member Profile: Hope for Heather

Hope for Heather was established in memory of Heather Weeks, a young woman who lost her life to colon cancer but spent her 20s working on behalf of women with ovarian cancer. Heather’s family started the organization in March of 2009. Their original goal was to raise about $1,000 a year for ovarian cancer research; … Continued

Community

Treatment in New Study on Mice with Ovarian Cancer has Posi...

Treatment in New Study on Mice with Ovarian Cancer has Positive Results

A targeted drug delivery system developed at Rutgers University could possibly make ovarian cancer more treatable.  The study results published in Clinical Cancer Research also indicated the new system could increase survival rates in ovarian cancer.  Read the full article here.    

Research

New OCRF Research on Ovarian Cancer Proliferation, Migratio...

New OCRF Research on Ovarian Cancer Proliferation, Migration, and Response to Therapy

Research funded by Ovarian Cancer Research Fund shows that adipose derived stromal cells derived from the human omentum can promote ovarian cancer proliferation, migration, chemoresistance and radiation resistance in-vitro. The research, funded in part through an OCRF grant to senior author Ann Klopp, MD, PhD was published online last week in PLoS One. The researchers hypothesized … Continued

Research

OCRF Research Sheds Light on Ovarian Cancer Origins in BRCA...

OCRF Research Sheds Light on Ovarian Cancer Origins in BRCA Mutation Carriers

A team of current and former OCRF grantees at Brigham and Women’s Hospital, Harvard Medical School and Dana-Farber Cancer Institute has developed genetically engineered mouse models of high-grade serous ovarian cancer that shed light on the pathogenesis of ovarian cancer for BRCA1/2 mutation carriers.  These models, which target the cell of origin (fallopian tube secretory cells) and recreate key genetic … Continued

OCRA News

Supreme Court to Consider Two Birth Control Lawsuits

Supreme Court to Consider Two Birth Control Lawsuits

The Supreme Court recently announced that it will hear two cases involving insurance coverage for birth control. The Alliance weighed in on one of these cases, arguing that oral contraceptives are a proven way to prevent ovarian cancer and should therefore be made available to women who wish to reduce their risk. Our CEO Calaneet … Continued

Advocacy

Scientists Ask: Does Ovarian Cancer Have a Smell?

Scientists Ask: Does Ovarian Cancer Have a Smell?

George Preti, who works at the Monell Chemical Senses Center as an organic chemist, and an interdisciplinary team that includes physicists and veterinarians at the University of Pennsylvania are using an electronic box to explore whether cancer has a smell.  In diseases that affect our metabolism, we secrete smells that can be indicative of what … Continued

Research

Partner Member Profile: Ovacome

Partner Member Profile: Ovacome

In 1999, Frieda Hooper was diagnosed with ovarian cancer. Frustrated with the lack of educational and supportive resources available, Hooper formed a support group for women with ovarian cancer in the Tampa Bay area, under the American Cancer Society. Rapidly growing in popularity, Ovacome started meeting independently of the American Cancer Society, eventually becoming an … Continued

Community

OCRF Research Shows that Combining Targeted Agents is Effec...

OCRF Research Shows that Combining Targeted Agents is Effective Against Ovarian Cancer

New research funded in part by OCRF has shown that combining microRNA and siRNAs may be an effective new approach to developing better targeted therapies for ovarian cancer.  The research was reported in the November 2013 issue of Cancer Discovery, where the findings were also highlighted in an editorial commentary.  The research was funded in … Continued

OCRA News

Use of a Chemoresponse Assay Improves Clinical Outcomes

Use of a Chemoresponse Assay Improves Clinical Outcomes

Research published in the November 2013 issue of Gynecologic Oncology reports that the use of the chemoresponse assay ChemoFx can lead to improved clinical outcomes for women undergoing treatment for ovarian cancer. The goal of this clinical trial, which took nearly ten years to complete, was to determine the association of chemoresponse assay results with … Continued

Research

Quality of life: Primary Debulking Surgery versus Neo-adjuv...

Quality of life: Primary Debulking Surgery versus Neo-adjuvant Chemotherapy

An international group of researchers examined quality of life factors for ovarian cancer patients enrolled in a large European clincial trial (EORTC 55971).  They compared the quality of life patients who had primary debulking surgery versus those who had neo-adjuvant chemotherapy, followed by surgery. The results, which are published in the journal Gynecologic Oncology, showed … Continued

Research

Stay Informed

Get email updates about research news, action alerts, and ways to join the fight.

We care about your data. Read our privacy policy.